uniQure (NASDAQ:QURE) Downgraded to Sell Rating by Wall Street Zen

uniQure (NASDAQ:QURE) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

QURE has been the topic of several other research reports. Royal Bank Of Canada lowered their price target on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research report on Monday, November 3rd. Benchmark reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. HC Wainwright dropped their target price on uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Mizuho lifted their price target on uniQure from $30.00 to $60.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Finally, The Goldman Sachs Group decreased their price objective on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $64.42.

uniQure Stock Performance

Shares of QURE opened at $21.33 on Monday. uniQure has a 1 year low of $6.62 and a 1 year high of $71.50. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The stock’s fifty day moving average price is $44.57 and its two-hundred day moving average price is $26.25. The firm has a market cap of $1.33 billion, a PE ratio of -4.86 and a beta of 0.59.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. On average, equities research analysts forecast that uniQure will post -3.75 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 226,316 shares of the firm’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the completion of the sale, the chief executive officer directly owned 651,454 shares in the company, valued at $27,009,282.84. This trade represents a 25.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total value of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares in the company, valued at approximately $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 314,560 shares of company stock valued at $12,362,568 in the last three months. Corporate insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Institutional investors have recently added to or reduced their stakes in the company. Private Trust Co. NA purchased a new position in uniQure during the third quarter valued at $28,000. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the period. CIBC Private Wealth Group LLC bought a new stake in uniQure during the third quarter worth about $50,000. Main Management ETF Advisors LLC grew its holdings in uniQure by 1.6% in the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 912 shares during the period. Finally, Knott David M Jr bought a new position in shares of uniQure during the third quarter valued at approximately $117,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.